JETA Molecular BV

JETA Molecular BV is a molecular diagnostics company specializing in transplantation medicine, with particular focus on post-transplant monitoring solutions. The company develops and commercializes in vitro diagnostic (IVD) assays and software for early detection of transplant rejection and disease relapse following hematopoietic stem cell transplantation (HSCT) and solid organ transplantation. Core product lines include QTRACE® chimerism analysis systems utilizing quantitative PCR (qPCR) technology with 80 INDEL assays for recipient-derived white blood cell monitoring, DigitalTRACE™ digital PCR (dPCR) assays for sensitive chimerism detection, and HLA TRACE™ assays for detecting HLA loss of heterozygosity (LOH) post-HSCT. The company also offers TRACE Analysis™ software for qPCR data analysis, protocol generation, longitudinal sample tracking, and LIMS integration. JETA's solutions enable clinicians to adjust immunosuppression regimens, optimize graft survival, and improve patient outcomes. The company was founded by researchers with extensive expertise in IVD/CE-marked assay development, ASR/GPR designation, and RUO molecular diagnostic kits for transplantation and human genetic testing. JETA maintains collaborations with key opinion leaders in stem cell and solid organ transplantation. The company operates as a European entity based in Utrecht, The Netherlands, with product distribution through established diagnostic partners.